Navigation Links
Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009

New non-drug procedure for severe asthma featured in eight presentations at annual conference in San Diego

SUNNYVALE, Calif., May 6 /PRNewswire/ -- Asthmatx released today the schedule of presentations featuring its novel Alair(R) Bronchial Thermoplasty System at ATS 2009, the International Conference of the American Thoracic Society (ATS), which will take place in San Diego, Calif., May 15-20. The schedule includes the one year results from the pivotal AIR2 Trial, which was designed to evaluate the safety and effectiveness of bronchial thermoplasty delivered by the Alair System, which is an investigational procedure that may change the standard of care for millions of patients suffering from asthma.

"We're looking forward to an exciting ATS meeting with numerous scientific presentations focusing on bronchial thermoplasty and its potential to elevate the standard of care for patients suffering from severe asthma," said Glen French, CEO of Asthmatx. "The selection by the ATS Program Committee of the AIR2 data for inclusion in the late breaking clinical trials session further reflects the importance of these data to the asthma community."

The full schedule of oral and poster presentations surrounding bronchial thermoplasty at ATS 2009 include:

    Monday, May 18, 2009

    ORAL PRESENTATIONS: 1:30 - 4:00 PM

    Session B92 Mini-Symposium: New treatment approaches for asthma and

    3:20-3:35 PM      Efficacy of Bronchial Thermoplasty (BT) in Patients with
                      Severe Asthma: The AIR2 Trial, Mario Castro, MD, St.
                      Louis, MO

    3:35-3:55 PM      "Bronchial Thermoplasty," Invited Featured Speaker:
                      Gerard Cox, MB, Hamilton, ON, Canada

    POSTER PRESENTATIONS: 8:15 AM - 4:00 PM (Authors will be at their
     respective posters from 10:45 AM -12:30 PM)

    Session B31: Asthma Therapeutics -- Studies in Humans

        -- Bronchial Thermoplasty, a Novel Therapeutic Procedure for Severe
           Asthma; A Detailed Procedure and Technique Discussion, Martin
           Mayse, MD, St. Louis, MO
        -- AIR2 Trial: Execution of a Sham-Controlled Double-Blind Study of a
           Novel Device for the Treatment of Severe Asthma, Gerard Cox, MB,
           Hamilton, ON, Canada
        -- Asthma-Related ER Visits and Hospitalizations Following Bronchial
           Thermoplasty (BT) in Patients with Severe, Symptomatic Asthma,
           Michael Wechsler, MD, Boston, MA
        -- Safety of Bronchial Thermoplasty (BT) in Patients with Severe,
           Symptomatic Asthma: Positive Safety Profile in the AIR2 Trial,
           Pallav Shah, MD, London, UK
        -- Long Term Safety of Bronchial Thermoplasty (BT): 3 year Data from
           Multiple Studies, Gerard Cox, MB, Hamilton, ON, Canada

    Tuesday, May 19, 2009



    2:45 - 3:10 PM    Bronchial Thermoplasty as Treatment for Severe Asthma:
                      Results of a Multicenter, Randomized, Sham-Controlled
                      Clinical Trial, Mario Castro, MD, St. Louis, MO

About Bronchial Thermoplasty Delivered by the Alair System

Bronchial thermoplasty is a novel non-drug treatment for asthma. The treatment is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair Catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the amount of airway smooth muscle that narrows the airways in patients with asthma during an asthma attack. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia and the patient returns home the same day. In the period immediately following bronchial thermoplasty, there is an expected increase and worsening of respiratory-related symptoms, which are of the type expected following bronchoscopy in patients with asthma. These typically occur within a day of the procedure and resolve on average within 7 days with standard care.

CAUTION: Alair System is an Investigational Device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.

Alair is a registered trademark of Asthmatx, Inc.

About Asthmatx

Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System from Asthmatx was awarded "Best of 2006" by Popular Science Magazine and bronchial thermoplasty was named one of the "Top Ten Medical Innovations for 2007" by the prestigious Cleveland Clinic Foundation. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit

SOURCE Asthmatx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
2. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
3. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
4. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
7. Pivotal Emory study focuses on teens at risk for psychosis
8. Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimers Monoclonal Antibody Platform
9. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
10. Pioneer(R) Surgical Technologys NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
11. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
Post Your Comments:
(Date:11/28/2015)... Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... new fully customizable media panels to choose from, the possibilities are endless. Users have ... and more. With the ProPanel: Pulse masking effects, users are sure to get heads ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology: